Replimune Group (NASDAQ:REPL) Shares Gap Up to $11.03

Replimune Group, Inc. (NASDAQ:REPL)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $11.03, but opened at $11.27. Replimune Group shares last traded at $11.43, with a volume of 15,854 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on REPL shares. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. Wedbush restated an “outperform” rating and set a $16.00 price target on shares of Replimune Group in a research report on Thursday, June 6th. JPMorgan Chase & Co. cut their price target on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research report on Monday. Finally, Barclays lifted their price objective on shares of Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Friday, June 7th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and an average price target of $16.20.

Replimune Group Stock Up 3.6 %

The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a 50 day simple moving average of $10.19 and a two-hundred day simple moving average of $8.38. The company has a market capitalization of $701.97 million, a PE ratio of -3.40 and a beta of 1.22.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Research analysts expect that Replimune Group, Inc. will post -3.08 EPS for the current year.

Insider Transactions at Replimune Group

In related news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares in the company, valued at $1,028,760.26. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently made changes to their positions in the stock. Quest Partners LLC boosted its holdings in Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares in the last quarter. Algert Global LLC boosted its stake in shares of Replimune Group by 5.4% during the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after acquiring an additional 4,340 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after acquiring an additional 4,946 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Replimune Group by 72.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after purchasing an additional 4,975 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its holdings in Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after purchasing an additional 5,410 shares during the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.